New Delhi: Central Council for Research in Ayurvedic Sciences (CCRAS), the research council under the Ministry of Ayush is developing new drugs for different disease conditions. These are AYUSH Manas for Mental retardation/cognitive deficit, AYUSH QOL for improving the quality of life of Cancer patients.
AYUSH Rasayan A & B in geriatric health
AYUSH M-3 for Migraine
AYUSH SL for Filariasis
AYUSH A for Bronchial Asthma
AYUSH D for Type II Diabetes Miletus
Carctol S for Cancer
AYUSH K1 for Chronic Kidney Diseases
Ayurveda drug for Non-Alcoholic fatty liver disease
Ayurveda drug as an adjuvant to ATT for hepatoprotection
These formulations are at different phases of drug development.
Commercialization of drugs:
Further CCRAS has commercialized already developed products namely Ayush-82 for Type –II Diabetes and Ayush SG for Rheumatoid arthritis NRDC in the last two years and now these formulations are already available in the market for general the public which are cost-effective and the people are using these formulations for diabetes and Rheumatoid arthritis. The Council has also commercialized AYUSH 64.
CCRAS one project each in Collaboration Clinical Research, Medicinal plant Research Drug standardization, Literary Research have been completed. Total 4 projects have been completed during October 2018.
CCRAS has completed Clinical Research in 1 IMR project. 1 IMR project of Drug Standardization Program and 1 IMR project of Clinical Research have been initiated.
Officials from CCRS in Siddha attended and presented the research work of the IMR project entitled “Geo-chemical characterization of Muppu” in the first National Bio-Medical Research competition on the occasion of 87th anniversary of Dr. APJ Abdul Kalam organized by AIIMS, Rishikesh held on 15th October, 2018 and won the Yong Researcher award.
Swasthya Rakshan Program has been executed through 7 CCRS Institutes/Units in 3 states 2 union territories. 12 locations were covered and medical care and awareness about hygiene and health was also provided to the people.